Multiple functions of USP18

Cell Death and Disease

Volumn 7, Issue 11, 2016, Pages

  Honke, Nadine ^a   Shaabani, Namir ^a,b   Zhang, Dong Er ^c   Hardt, Cornelia ^a   Lang, Karl S ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD11B ANTIGEN; PEPTIDASE; UBIQUITIN SPECIFIC PEPTIDASE 18; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; PROTEINASE;

ADAPTIVE IMMUNITY; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL MATURATION; CODON; DENDRITIC CELL; EXON; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; LUNG FIBROBLAST; MALIGNANT NEOPLASM; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; START CODON; TH17 CELL; VIRUS INFECTION; VIRUS REPLICATION; ANIMAL; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; CHEMISTRY; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; AUTOIMMUNE DISEASES; CARCINOGENESIS; ENDOPEPTIDASES; HUMANS; MODELS, BIOLOGICAL; VIRUS DISEASES;

EID: 85025607601     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.326     Document Type: Review

References (95)

1. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One 2011; 6: e22200.
2. Burkart C, Arimoto K, Tang T, Cong X, Xiao N, Liu YC et al. Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-lambda and elevated secretion of Cxcl10. EMBO Mol Med 2013; 5: 967–982.
3. Liu LQ, Ilaria R Jr., Kingsley PD, Iwama A, van Etten RA, Palis J et al. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 1999; 19: 3029–3038.
4. Schwer H, Liu LQ, Zhou L, Little MT, Pan Z, Hetherington CJ et al. Cloning and characterization of a novel human ubiquitin-specific protease, a homologue of murine UBP43 (Usp18). Genomics 2000; 65: 44–52.
5. Zhang X, Shin J, Molitor TW, Schook LB, Rutherford MS. Molecular responses of macrophages to porcine reproductive and respiratory syndrome virus infection. Virology 1999; 262: 152–162.
6. Kang D, Jiang H, Wu Q, Pestka S, Fisher PB. Cloning and characterization of human ubiquitin-processing protease-43 from terminally differentiated human melanoma cells using a rapid subtraction hybridization protocol RaSH. Gene 2001; 267: 233–242.
7. Baker RT, Wang XW, Woollatt E, White JA, Sutherland GR. Identification, functional characterization, and chromosomal localization of USP15, a novel human ubiquitin-specific protease related to the UNP oncoprotein, and a systematic nomenclature for human ubiquitin-specific proteases. Genomics 1999; 59: 264–274.
8. Ye Y, Scheel H, Hofmann K, Komander D. Dissection of USP catalytic domains reveals five common insertion points. Mol Biosyst 2009; 5: 1797–1808.
9. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006; 25: 2358–2367.
10. Dauphinee SM, Richer E, Eva MM, McIntosh F, Paquet M, Dangoor D et al. Contribution of increased ISG15, ISGylation and deregulated type I IFN signaling in Usp18 mutant mice during the course of bacterial infections. Genes Immun 2014; 15: 282–292.
11. Richer E, Prendergast C, Zhang DE, Qureshi ST, Vidal SM, Malo D. N-ethyl-N-nitrosourea-induced mutation in ubiquitin-specific peptidase 18 causes hyperactivation of IFN-alphass signaling and suppresses STAT4-induced IFN-gamma production, resulting in increased susceptibility to Salmonella typhimurium. J Immunol 2010; 185: 3593–3601.
12. Burkart C, Fan JB, Zhang DE. Two independent mechanisms promote expression of an N-terminal truncated USP18 isoform with higher DeISGylation activity in the nucleus. J Biol Chem 2012; 287: 4883–4893.
13. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002; 277: 9976–9981.
14. Honke N, Shaabani N, Cadeddu G, Sorg UR, Zhang DE, Trilling M et al. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol 2011; 13: 51–57.
15. Honke N, Shaabani N, Zhang DE, Iliakis G, Xu HC, Haussinger D et al. Usp18 driven enforced viral replication in dendritic cells contributes to break of immunological tolerance in autoimmune diabetes. PLoS Pathog 2013; 9: e1003650.
16. Liu X, Li H, Zhong B, Blonska M, Gorjestani S, Yan M et al. USP18 inhibits NF-kappaB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex. J Exp Med 2013; 210: 1575–1590.
17. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006; 131: 1584–1591.
18. Ritchie KJ, Malakhov MP, Hetherington CJ, Zhou L, Little MT, Malakhova OA et al. Dysregulation of protein modification by ISG15 results in brain cell injury. Genes Dev 2002; 16: 2207–2212.
19. Li L, Lei QS, Zhang SJ, Kong LN, Qin B. Suppression of USP18 potentiates the anti-HBV activity of interferon alpha in HepG2.2.15 cells via JAK/STAT signaling. PLoS One 2016; 11: e0156496.
20. Li XL, Blackford JA, Judge CS, Liu M, Xiao W, Kalvakolanu DV et al. RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5 A system in attenuation of the interferon response. J Biol Chem 2000; 275: 8880–8888.
21. Kim KI, Malakhova OA, Hoebe K, Yan M, Beutler B, Zhang DE. Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling. J Immunol 2005; 175: 847–854.
22. MacParland SA, Ma XZ, Chen L, Khattar R, Cherepanov V, Selzner M et al. Lipopolysaccharide and tumor necrosis factor Alpha inhibit interferon signaling in hepatocytes by increasing ubiquitin-like protease 18 (USP18) expression. J Virol 2016; 90: 5549–5560.
23. Yang Z, Xian H, Hu J, Tian S, Qin Y, Wang RF et al. USP18 negatively regulates NF-kappaB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms. Sci Rep 2015; 5: 12738.
24. Tokarz S, Berset C, La Rue J, Friedman K, Nakayama K, Zhang DE et al. The ISG15 isopeptidase UBP43 is regulated by proteolysis via the SCFSkp2 ubiquitin ligase. J Biol Chem 2004; 279: 46424–46430.
25. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438–449.
26. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 2003; 17: 455–460.
27. Potu H, Sgorbissa A, Brancolini C. Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. Cancer Res 2010; 70: 655–665.
28. Yim HY, Yang Y, Lim JS, Lee MS, Zhang DE, Kim KI. The mitochondrial pathway and reactive oxygen species are critical contributors to interferon-alpha/beta-mediated apoptosis in Ubp43-deficient hematopoietic cells. Biochem Biophys Res Commun 2012; 423: 436–440.
29. Rempel LA, Austin KJ, Ritchie KJ, Yan M, Shen M, Zhang DE et al. Ubp43 gene expression is required for normal Isg15 expression and fetal development. Reprod Biol Endocrinol 2007; 5: 13.
30. Knobeloch KP, Utermohlen O, Kisser A, Prinz M, Horak I. Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice. Mol Cell Biol 2005; 25: 11030–11034.
31. Yim HY, Park C, Lee YD, Arimoto K, Jeon R, Baek SH et al. Elevated response to type I IFN enhances RANKL-mediated osteoclastogenesis in Usp18-knockout mice. J Immunol 2016; 196: 3887–3895.
32. Ritchie KJ, Hahn CS, Kim KI, Yan M, Rosario D, Li L et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med 2004; 10: 1374–1378.
33. Ketscher L, Hannss R, Morales DJ, Basters A, Guerra S, Goldmann T et al. Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 conjugation and viral resistance. Proc Natl Acad Sci USA 2015; 112: 1577–1582.
34. Cong XL, Lo MC, Reuter BA, Yan M, Fan JB, Zhang DE. Usp18 promotes conventional CD11b+ dendritic cell development. J Immunol 2012; 188: 4776–4781.
35. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8: 337–348.
36. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996; 274: 1652–1659.
37. Zhu Y, Carroll M, Papa FR, Hochstrasser M, D'Andrea AD. DUB-1, a deubiquitinating enzyme with growth-suppressing activity. Proc Natl Acad Sci USA 1996; 93: 3275–3279.
38. Finley D, Chau V. Ubiquitination. Annu Rev Cell Biol 1991; 7: 25–69.
39. Miranda M, Dionne KR, Sorkina T, Sorkin A. Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter. Mol Biol Cell 2007; 18: 313–323.
40. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995; 9: 2723–2735.
41. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761–771.
42. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet 1996; 30: 405–439.
43. Wilkinson KD. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 1997; 11: 1245–1256.
44. Narasimhan J, Potter JL, Haas AL. Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct from that of ubiquitin. J Biol Chem 1996; 271: 324–330.
45. Ritchie KJ, Zhang DE. ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol 2004; 15: 237–246.
46. Yuan W, Krug RM. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 2001; 20: 362–371.
47. Kim KI, Giannakopoulos NV, Virgin HW, Zhang DE. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol 2004; 24: 9592–9600.
48. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA et al. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc Natl Acad Sci USA 2004; 101: 7578–7582.
49. Dao CT, Zhang DE. ISG15: a ubiquitin-like enigma. Front Biosci 2005; 10: 2701–2722.
50. Zou W, Zhang DE. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem 2006; 281: 3989–3994.
51. Ait-Ali T, Wilson AW, Finlayson H, Carre W, Ramaiahgari SC, Westcott DG et al. Functional analysis of the porcine USP18 and its role during porcine arterivirus replication. Gene 2009; 439: 35–42.
52. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C et al. Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature 2015; 517: 89–93.
53. Speer SD, Li Z, Buta S, Payelle-Brogard B, Qian L, Vigant F et al. ISG15 deficiency and increased viral resistance in humans but not mice. Nat Commun 2015; 7: 11496.
54. Warsi J, Hosseinzadeh Z, Elvira B, Pelzl L, Shumilina E, Zhang DE et al. USP18 Sensitivity of Peptide Transporters PEPT1 and PEPT2. PLoS One 2015; 10: e0129365.
55. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014; 14: 36–49.
56. Osiak A, Utermohlen O, Niendorf S, Horak I, Knobeloch KP. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol Cell Biol 2005; 25: 6338–6345.
57. Kim KI, Yan M, Malakhova O, Luo JK, Shen MF, Zou W et al. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol 2006; 26: 472–479.
58. Francois-Newton V, Livingstone M, Payelle-Brogard B, Uze G, Pellegrini S. USP18 establishes the transcriptional and anti-proliferative interferon alpha/beta differential. Biochem J 2012; 446: 509–516.
59. Zou W, Kim JH, Handidu A, Li X, Kim KI, Yan M et al. Microarray analysis reveals that Type I interferon strongly increases the expression of immune-response related genes in Ubp43 (Usp18) deficient macrophages. Biochem Biophys Res Commun 2007; 356: 193–199.
60. Xu D, Lillico SG, Barnett MW, Whitelaw CB, Archibald AL, Ait-Ali T. USP18 restricts PRRSV growth through alteration of nuclear translocation of NF-kappaB p65 and p50 in MARC-145 cells. Virus Res 2012; 169: 264–267.
61. Kim JH, Luo JK, Zhang DE. The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J Immunol 2008; 181: 6467–6472.
62. Zhu Y, Qin B, Xiao C, Lu X, Chen L. Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients. Dig Dis Sci 2012; 57: 2355–2361.
63. Lenschow DJ, Giannakopoulos NV, Gunn LJ, Johnston C, O'Guin AK, Schmidt RE et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 2005; 79: 13974–13983.
64. Okumura A, Lu G, Pitha-Rowe I, Pitha PM. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci USA 2006; 103: 1440–1445.
65. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 2007; 104: 1371–1376.
66. Ma XZ, Bartczak A, Zhang J, He W, Shalev I, Smil D et al. Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis. J Virol 2014; 88: 6195–6204.
67. Asahina Y, Izumi N, Hirayama I, Tanaka T, Sato M, Yasui Y et al. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 2008; 134: 1396–1405.
68. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol 2010; 91: 382–388.
69. Li Y, Li S, Duan X, Liu B, Yang C, Zeng P et al. Activation of endogenous type I IFN signaling contributes to persistent HCV infection. Rev Med Virol 2014; 24: 332–342.
70. Rubartelli A, Lotze MT, Latz E, Manfredi A. Mechanisms of sterile inflammation. Front Immunol 2013; 4: 398.
71. Henrickson SE, Mempel TR, Mazo IB, Liu B, Artyomov MN, Zheng H et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol 2008; 9: 282–291.
72. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003; 18: 255–264.
73. Colonne PM, Sahni A, Sahni SK. Suppressor of cytokine signalling protein SOCS1 and UBP43 regulate the expression of type I interferon-stimulated genes in human microvascular endothelial cells infected with Rickettsia conorii. J Med Microbiol 2013; 62: 968–979.
74. Colonne PM, Sahni A, Sahni SK. Rickettsia conorii infection stimulates the expression of ISG15 and ISG15 protease UBP43 in human microvascular endothelial cells. Biochem Biophys Res Commun 2011; 416: 153–158.
75. Santin I, Eizirik DL. Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and beta-cell apoptosis. Diabetes Obes Metab 2013; 15: 71–81.
76. Santin I, Moore F, Grieco FA, Marchetti P, Brancolini C, Eizirik DL. USP18 is a key regulator of the interferon-driven gene network modulating pancreatic beta cell inflammation and apoptosis. Cell Death Dis 2012; 3: e419.
77. Bendtzen K. Critical review: assessment of interferon-beta immunogenicity in multiple sclerosis. J Interferon Cytokine Res 2010; 30: 759–766.
78. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898–904.
79. Goldmann T, Zeller N, Raasch J, Kierdorf K, Frenzel K, Ketscher L et al. USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J 2015; 34: 1612–1629.
80. Takata K, Ginhoux F. Poised for action: USP18 restrains microglial activation in the white matter. EMBO J 2015; 34: 1603–1605.
81. Malhotra S, Bustamante MF, Perez-Miralles F, Rio J, Ruiz de Villa MC, Vegas E et al. Search for specific biomarkers of IFNbeta bioactivity in patients with multiple sclerosis. PLoS One 2011; 6: e23634.
82. Malhotra S, Morcillo-Suarez C, Nurtdinov R, Rio J, Sarro E, Moreno M et al. Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-beta treatment. Eur J Neurol 2013; 20: 1390–1397.
83. Yan M, Luo JK, Ritchie KJ, Sakai I, Takeuchi K, Ren R et al. Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood 2007; 110: 305–312.
84. Sgorbissa A, Tomasella A, Potu H, Manini I, Brancolini C, Type I. IFNs signaling and apoptosis resistance in glioblastoma cells. Apoptosis 2011; 16: 1229–1244.
85. Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E et al. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARalpha and inhibits the growth of acute promyelocytic leukemia. Cancer Res 2010; 70: 9875–9885.
86. Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F et al. Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Mol Cancer Ther 2012; 11: 1968–1977.
87. Shahidul Makki M, Cristy Ruteshouser E, Huff V. Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target. Exp Cell Res 2013; 319: 612–622.
88. Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F et al. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 2008; 7: 3780–3788.
89. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006; 6: 776–788.
90. Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L et al. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 2004; 64: 8109–8115.
91. Manini I, Sgorbissa A, Potu H, Tomasella A, Brancolini C. The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis. Cancer Biol Ther 2013; 14: 1158–1166.
92. Duex JE, Comeau L, Sorkin A, Purow B, Kefas B. Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem 2011; 286: 25377–25386.
93. Hong B, Li H, Lu Y, Zhang M, Zheng Y, Qian J et al. USP18 is crucial for IFN-gamma-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Mol Cancer 2014; 13: 132.
94. Kim YH, Kim WT, Jeong P, Ha YS, Kang HW, Yun SJ et al. Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2. J Korean Med Sci 2014; 29: 351–356.
95. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010; 207: 2053–2063.